Indeed, due to venetoclax’s specific targeting of Bcl-2, tumor cells may shift their dependency to other anti-apoptotic proteins such as Bcl-XL, MCL-1 and Bfl-1 for survival (Shimony et al., 2022). This evidence concerns the gene BCL2A1 and neoplasm.